← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
vonoprazan
A02BC08
Adult Dosing
- 60mg orally once daily for healing of erosive esophagitis
- 60mg orally once daily for maintenance of healing of erosive esophagitis
- 20mg orally twice daily for eradication of H. pylori in combination with antibiotics
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Healing of erosive esophagitis
- Maintenance of healing of erosive esophagitis
- Treatment of non-erosive gastroesophageal reflux disease
- Eradication of H. pylori in combination with antibiotics
Mechanism of Action
- Potassium-competitive acid blocker
- Inhibits H+/K+ ATPase at the secretory surface of gastric parietal cells
- Reduces gastric acid secretion
Contraindications
- Hypersensitivity to vonoprazan or any component of the formulation
Adverse Reactions
- Diarrhea
- Abdominal pain
- Nausea
- Vomiting
- Dysgeusia
- Increased liver enzymes
Drug Interactions
- Decreases atazanavir and nelfinavir plasma concentrations
- May decrease absorption of ketoconazole and itraconazole
- Monitor INR with concomitant warfarin use
- May increase cilostazol plasma concentrations
Curated Content: Needs Vetting Before Put to Clinical Use